HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

508.484

-5.015-0.98%

Number of Gainers:17

Number of Losers:33

Number of Flat:5

PE:- -

High:516.134

Open:513.498

Low:507.279

Close:513.498

Loading ...

China Resources Mixc Lifestyle Services Ltd. Conducted Annual General Meeting

Legend Biotech Corporation Names Peter Salovey as Lead Independent Director

BRIEF-JPMorgan Chase & Co's Long Position In Wuxi Apptec H-Shares Increases To 7.12% On May 30 - HKEX

Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI

Jinke Smart Services Group Co. Ltd. Announces Securities Dealings Under Rule 22 Amid Possible Mandatory General Offer

Innovent's Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) Receives Second Nmpa Breakthrough Therapy Designation for Immuno-Resistant Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS

BRIEF-HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab

BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As Chairman

Tong Ren Tang Technologies Co Ltd - Resignation of Di Shu Bing as Chairman of Board

THOMSON REUTERS

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 200,000 Shares at HKD 8.7394 Each

South Manganese Investment Ltd. Announces Debt Reduction Proposal to Improve Financial Stability

South Manganese Investment Ltd - Target Is to Reduce Group's Indebtedness by RMB300 Mln to RMB500 Mln per Year

THOMSON REUTERS

South Manganese Investment - Board Has Approved a Debt Reduction Proposal of Company

THOMSON REUTERS

Zhaoke Ophthalmology Ltd. Secures FDA Clearance for IND Application of CsA Ophthalmic Gel for Dry Eye Disease Treatment

Zhaoke Ophthalmology Ltd - FDA Clearance of Ind Application for Csa Ophthalmic Gel

THOMSON REUTERS

Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study

MT Newswires Live

Innovent's Phase 1 Trial for Lung Cancer Drug Shows Manageable Safety, Long-Term Survival Benefits; Shares Surge 14%

MT Newswires Live

BUZZ-Hansoh hits near 4-year peak as its cancer drug gets UK marketing approval

Hansoh Pharmaceutical's Aumolertinib Mesilate Tablets Approved by UK MHRA for Marketing

Hansoh Pharmaceutical - Aumolertinib Mesilate Tablets Was Approved by Mhra for Marketing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":508.4835,"timestamp":1749189694027,"preClose":513.49805,"halted":0,"volume":464474481,"delay":0,"changeRate":-0.009765,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-5.014557,"latestTime":"06-06 14:01:34","open":513.49805,"high":516.1344,"low":507.27917,"amount":8014511005,"amplitude":0.017245,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749197400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":2.369138,"peRate":22.094004,"turnoverRate":0.00337,"increases":17,"decrements":34,"flats":3,"marketCap":2879390672192,"floatMarketCap":2266987805504},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":516.1344,"amplitude":0.017245,"preClose":513.49805,"low":507.27917,"pbRate":"2.369138","latestPrice":508.4835,"volume":464474481,"delay":0,"open":513.49805,"prevYearClose":446.93042,"prevWeekClose":496.286,"prevMonthClose":496.286,"prevQuarterClose":505.776,"fiveDayClose":496.286,"twentyDayClose":480.539,"sixtyDayClose":530.16,"secType":"PLATE","market":"HK","turnoverRate":0.00337,"peRate":22.094004,"marketCap":2879390672192,"floatMarketCap":2266987805504,"timestamp":1749189694027,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":17,"down":33,"flat":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541305075","title":"China Resources Mixc Lifestyle Services Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541305075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541305075?lang=en_us&edition=fundamental","pubTime":"2025-06-05 21:35","pubTimestamp":1749130549,"startTime":"0","endTime":"0","summary":"China Resources Mixc Lifestyle Services Ltd. held its annual general meeting on 5 June 2025. The proposal to receive and consider the audited financial statements, directors' report, and independent auditor's report for the year ended 31 December 2024 was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Mixc Lifestyle Services Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL8h1vwF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456827905.SGD","LU0738912210.USD","LU2088748020.USD","LU0791591158.USD","LU0791590937.USD","BK1555","LU0173614495.USD","LU0594300419.USD","LU1880383366.USD","LU0348825331.USD","LU2088748376.SGD","BK1589","LU0501845795.SGD","LU0880133367.SGD","BK1240","LU0048597586.USD","LU0051755006.USD","BK1570","LU1807302812.USD","LU1008478684.HKD","LU1152091168.USD","LU0414403682.SGD","LU0359201612.USD","LU0287142896.SGD","LU0650527681.SGD","01109","LU0359202008.SGD","LU2088748293.HKD","SG9999009997.SGD","LU2088747998.USD","LU1366334578.USD","SG9999014674.SGD","SG9999010052.SGD","01209","LU0417516902.SGD","IE0008368742.USD","BK1583","BK1258","LU0370786039.SGD","LU0251144936.SGD","LU0067412154.USD","LU1366334651.USD","LU1152091754.HKD","LU0594300179.USD","SG9999010078.USD","LU0605514214.HKD","LU2088747725.USD","LU1993786604.SGD","BK1521","BK1542"],"gpt_icon":0},{"id":"2541020258","title":"Legend Biotech Corporation Names Peter Salovey as Lead Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2541020258","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541020258?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:22","pubTimestamp":1749126168,"startTime":"0","endTime":"0","summary":"Legend Biotech Corporation has announced the appointment of Peter Salovey, Ph.D., as Lead Independent Director, effective June 5, 2025. Dr. Salovey, President Emeritus of Yale University, has been serving as an independent director on the company's Board since August 2024. In his new role, he will act as a key liaison among the Board, management, and shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDLbMQPcZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","HK0000306701.USD","01548","BK1583","HK0000306685.HKD","HK0000320223.HKD","LEGN","HK0000320264.USD","BK1141","BK4139","BK1576","BK4585","BK4505"],"gpt_icon":0},{"id":"2541021021","title":"BRIEF-JPMorgan Chase & Co's Long Position In Wuxi Apptec H-Shares Increases To 7.12% On May 30 - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2541021021","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541021021?lang=en_us&edition=fundamental","pubTime":"2025-06-05 18:34","pubTimestamp":1749119657,"startTime":"0","endTime":"0","summary":"BRIEF-JPMorgan Chase & Co's Long Position In Wuxi Apptec H-Shares Increases To 7.12% On May 30 - HKEXJune 5  - JPMORGAN CHASE & CO'S LONG POSITION IN H-SHARES OF WUXI APPTEC INCREASES TO 7.12% ON MAY 30 FROM 6.59% - HKEXFurther company coverage: 2359.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S70WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2495084118.USD","LU2125910500.SGD","LU2242644610.SGD","LU2488822045.USD","LU0456842615.SGD","LU0052750758.USD","LU1969619763.USD","LU2328871848.SGD","BK1576","LU0708995583.HKD","LU1997245177.USD","BK1141","BK1583","LU1046422090.SGD","603259","LU2045819591.USD","LU0320764599.SGD","LU1997244956.HKD","BK0216","LU1997245094.SGD","02359"],"gpt_icon":0},{"id":"2541023107","title":"Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI","url":"https://stock-news.laohu8.com/highlight/detail?id=2541023107","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541023107?lang=en_us&edition=fundamental","pubTime":"2025-06-05 17:26","pubTimestamp":1749115564,"startTime":"0","endTime":"0","summary":"Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI. On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets , has received marketing authorization from the Medicines and Healthcare products Regulatory Agency  of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer  with activating epidermal growth factor receptor  mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL8rFL49:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1191","BK1589","BK1583"],"gpt_icon":0},{"id":"2541239870","title":"Jinke Smart Services Group Co. Ltd. Announces Securities Dealings Under Rule 22 Amid Possible Mandatory General Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2541239870","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541239870?lang=en_us&edition=fundamental","pubTime":"2025-06-05 17:23","pubTimestamp":1749115390,"startTime":"0","endTime":"0","summary":"Jinke Smart Services Group Co. Ltd. has disclosed recent internal dealings under Rule 22 of the Hong Kong Code on Takeovers and Mergers. On 4 June 2025, Yunnan International Trust Co., Ltd., a Class  associate connected with the Offeree company, sold various blocks of shares in Jinke Smart Services Group. These transactions have adjusted Yunnan International Trust's resultant balance to 9,254,700 shares, representing 1.5500% of the class. Yunnan International Trust Co. is ultimately owned by Yunnan Provincial State-owned Financial Capital Holding Group Co., Ltd. All dealings were made for its own account.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jinke Smart Services Group Co. Ltd. published the original content used to generate t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL8Pxmf3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","BK0273","BK1583","BK0174","BK1258","BK1229","BK1542","09666","000656"],"gpt_icon":0},{"id":"2541090441","title":"Innovent's Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) Receives Second Nmpa Breakthrough Therapy Designation for  Immuno-Resistant Squamous Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2541090441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541090441?lang=en_us&edition=fundamental","pubTime":"2025-06-05 08:23","pubTimestamp":1749082994,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nTUAGHKW5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","01801","BK1583","LU2328871848.SGD","BK1161","LU1969619763.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2541097438","title":"BRIEF-HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2541097438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541097438?lang=en_us&edition=fundamental","pubTime":"2025-06-05 07:47","pubTimestamp":1749080867,"startTime":"0","endTime":"0","summary":"BRIEF-HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With SintilimabJune 5 (Reuters) - HUTCHMED (China) Ltd 0013.HK:NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WIT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1588","LU1969619763.USD","LU2328871848.SGD","BK1191","BK1587","BK1161","00013","BK1589","01801","LU2488822045.USD"],"gpt_icon":0},{"id":"2541092127","title":"BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2541092127","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541092127?lang=en_us&edition=fundamental","pubTime":"2025-06-05 07:01","pubTimestamp":1749078081,"startTime":"0","endTime":"0","summary":"BRIEF-Tong REN Tang Technologies Announces Resignation Of Di Shu Bing As ChairmanJune 5 (Reuters) - Tong Ren Tang Technologies Co Ltd 1666.HK:RESIGNATION OF DI SHU BING AS CHAIRMAN OF BOARDFurther company coverage: 1666.HK ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S7109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01666","BK1583","BK1606","BK1515","BK1191"],"gpt_icon":0},{"id":"2541929180","title":"Tong Ren Tang Technologies Co Ltd - Resignation of Di Shu Bing as Chairman of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2541929180","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541929180?lang=en_us&edition=fundamental","pubTime":"2025-06-05 06:59","pubTimestamp":1749077956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S7109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1606","BK1191","BK1583","01666"],"gpt_icon":0},{"id":"2540069128","title":"HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 200,000 Shares at HKD 8.7394 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2540069128","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540069128?lang=en_us&edition=fundamental","pubTime":"2025-06-04 21:34","pubTimestamp":1749044046,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, revealing the repurchase of 200,000 shares to be held as treasury shares. The shares were repurchased at a total price of HKD 1,747,870, with an average price of HKD 8.7394 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL2SgVz5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"gpt_icon":0},{"id":"2540050272","title":"South Manganese Investment Ltd. Announces Debt Reduction Proposal to Improve Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050272?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:07","pubTimestamp":1749035265,"startTime":"0","endTime":"0","summary":"South Manganese Investment Ltd. has announced a debt reduction proposal approved at a board meeting on June 4, 2025. The company plans to present the proposal for shareholder approval at a Special General Meeting . The initiative aims to enhance the company's credit rating, reduce finance costs, improve cash flows, and strengthen its capital structure. The proposal involves utilizing the group's available free cash flows to repay borrowings and optimize asset management, targeting a reduction of RMB300 million to RMB500 million in indebtedness annually. The goal is to lower the gearing ratio to 50% or below within the next five years while maintaining normal operations. A circular and notice of the SGM are expected to be dispatched to shareholders by June 30, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDLccLtX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01091","BK1190","BK1583","BK1592"],"gpt_icon":0},{"id":"2540263050","title":"South Manganese Investment Ltd - Target Is to Reduce Group's Indebtedness by RMB300 Mln to RMB500 Mln per Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2540263050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540263050?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:05","pubTimestamp":1749035154,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70ES:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1592","BK1190","01091"],"gpt_icon":0},{"id":"2540050288","title":"South Manganese Investment - Board Has Approved a Debt Reduction Proposal of Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050288?lang=en_us&edition=fundamental","pubTime":"2025-06-04 19:05","pubTimestamp":1749035154,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70ES:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1592","01091","BK1190"],"gpt_icon":0},{"id":"2540705409","title":"Zhaoke Ophthalmology Ltd. Secures FDA Clearance for IND Application of CsA Ophthalmic Gel for Dry Eye Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540705409","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540705409?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:08","pubTimestamp":1749031684,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology Ltd. has announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for its core product, Cyclosporine  Ophthalmic Gel. This gel is being developed for the treatment of moderate-to-severe dry eye disease and will advance to a Phase III, multicenter, randomized, double-masked, active-controlled study. The FDA's clearance allows Zhaoke to incorporate data from its completed pivotal Phase III clinical trial  and ongoing Phase III trial in China into its U.S. development plan. This regulatory milestone marks a significant step forward for Zhaoke in potentially improving patient compliance and quality of life with its innovative once-daily application gel.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9fqH1V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","06622","BK1587","BK1191","BK1574"],"gpt_icon":0},{"id":"2540405408","title":"Zhaoke Ophthalmology Ltd - FDA Clearance of Ind Application for Csa Ophthalmic Gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2540405408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540405408?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:06","pubTimestamp":1749031586,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1191","BK1587","06622","BK1574"],"gpt_icon":0},{"id":"2540051652","title":"Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2540051652","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540051652?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:46","pubTimestamp":1749030408,"startTime":"0","endTime":"0","summary":"Genscript Biotech (HKG:1548) subsidiary Legend Biotech said one-third of patients with relapsed/refractory multiple myeloma in its ciltacabtagene autoleucel study showed progression-free survival for ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1576","HK0000306685.HKD","BK1141","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD","01548"],"gpt_icon":0},{"id":"2540799031","title":"Innovent's Phase 1 Trial for Lung Cancer Drug Shows Manageable Safety, Long-Term Survival Benefits; Shares Surge 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540799031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540799031?lang=en_us&edition=fundamental","pubTime":"2025-06-04 15:10","pubTimestamp":1749021006,"startTime":"0","endTime":"0","summary":"Innovent Biologics'  IBI363 medication for immunotherapy-resistant non-small cell lung cancer and wild-type lung adenocarcinoma showed a manageable safety profile, efficacy, and long-term survival benefits during its phase 1 study.The drug company presented the findings during the 2025 American Society of Clinical Oncology Conference, according to a Wednesday news release.IBI363 also showed breakthrough therapeutic potential from tumor response to long-term survival benefits for patients with immuno-resistant squamous non-small cell lung cancer, and wild-type lung adenocarcinoma, especially with those who smoked.Shares surged 14% during Wednesday's afternoon trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","BK1589","BK1161","LU2328871848.SGD","LU2488822045.USD","01801","BK1583"],"gpt_icon":0},{"id":"2540350010","title":"BUZZ-Hansoh hits near 4-year peak as its cancer drug gets UK marketing approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2540350010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540350010?lang=en_us&edition=fundamental","pubTime":"2025-06-04 13:49","pubTimestamp":1749016175,"startTime":"0","endTime":"0","summary":"BUZZ-Hansoh hits near 4-year peak as its cancer drug gets UK marketing approval ** Shares of Hansoh Pharmaceutical Group 3692.HK rise 3.8% to HK$27.5, their highest levels since August 2021** Stock marks biggest intraday pct gain since May 20, and on track for a third straight session of rise, if current trend holds ** Stock is fifth-biggest pct gainer on the Hang Seng Commerce & Industry Index .HSNC, which climbs 0.8% ** Hansoh says its innovative drug Aumolertinib Mesilate Tablets for lung cancer has been approved by the Medicines and Healthcare Products Regulatory Agency  in the UK for marketing** The Hang Seng Biotech Index .HSHKBIO rises 3.1% and the Hang Seng Index .HSI adds 0.5%** YTD, stock up 56.8%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nL2N3S704L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1583","BK1191","BK1589"],"gpt_icon":0},{"id":"2540038640","title":"Hansoh Pharmaceutical's Aumolertinib Mesilate Tablets Approved by UK MHRA for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540038640","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540038640?lang=en_us&edition=fundamental","pubTime":"2025-06-04 12:08","pubTimestamp":1749010133,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. has announced that its innovative drug, Aumolertinib Mesilate Tablets , has been approved by the Medicines and Healthcare Products Regulatory Agency  in the United Kingdom for marketing. Aumseqa is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer  with activating epidermal growth factor receptor  mutations, and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. This approval marks a significant milestone for Hansoh Pharmaceutical as it expands its presence in the UK market with its first innovative third-generation EGFR-TKI drug developed in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL72BkFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1589","03692"],"gpt_icon":0},{"id":"2540038637","title":"Hansoh Pharmaceutical - Aumolertinib Mesilate Tablets Was Approved by Mhra for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540038637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540038637?lang=en_us&edition=fundamental","pubTime":"2025-06-04 12:06","pubTimestamp":1749009993,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S702S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03692","BK1589","BK1191","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":106,"code":"91000000","status":"200"}]}}